Coronavirus: Vaccination

(asked on 30th June 2021) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what data his Department holds on the effectiveness of the (a) Pfizer, (b) AstraZeneca and (c) Moderna covid-19 vaccinations at reducing transmission of covid-19.


Answered by
Nadhim Zahawi Portrait
Nadhim Zahawi
This question was answered on 15th July 2021

Public Health England (PHE) publishes weekly COVID-19 vaccine surveillance reports which include the latest evidence on vaccine effectiveness against different outcomes. The following table shows the latest summary of evidence on vaccine effectiveness against different outcomes, including transmission, for Pfizer/BioNTech and University of Oxford/AstraZeneca as of 1 July.

Outcome

Vaccine Effectiveness

Pfizer/BioNTech

Oxford/AstraZeneca

1 dose

2 doses

1 dose

2 doses

Symptomatic disease

55-70%*

85-95%*

55-70%*

70-85%**

Hospitalisation

75-85%*

90-99%**

75-85%*

80-99%***

Mortality

70-80%**

95-99%**

75-85%**

75-99%***

Infection

55-70%**

70-90%***

60-70%***

No data

Transmission (secondary cases)^

45-50%***

No data

35-50%***

No data

Source: Table 3 https://www.gov.uk/government/publications/covid-19-vaccine-surveillance-report

Notes:

  1. *High Confidence - Evidence from multiple studies which is consistent and comprehensive
  2. **Medium Confidence - Evidence is emerging from a limited number of studies or with a moderately level of uncertainty
  3. ***Low Confidence - Little evidence is available at present and results are inconclusive
  4. ^effectiveness in reducing symptomatic secondary cases in households of a symptomatic index case

PHE plans to publish vaccine effectiveness data for Moderna when more evidence becomes available.

Reticulating Splines